CN104126785A - 一种具有降糖作用的组合物及其制备方法 - Google Patents
一种具有降糖作用的组合物及其制备方法 Download PDFInfo
- Publication number
- CN104126785A CN104126785A CN201410376269.XA CN201410376269A CN104126785A CN 104126785 A CN104126785 A CN 104126785A CN 201410376269 A CN201410376269 A CN 201410376269A CN 104126785 A CN104126785 A CN 104126785A
- Authority
- CN
- China
- Prior art keywords
- mycelium
- mushroom
- preparation
- composition
- ferment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 67
- 210000004369 blood Anatomy 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 103
- 244000234623 Coprinus comatus Species 0.000 claims abstract description 27
- 235000004439 Coprinus comatus Nutrition 0.000 claims abstract description 27
- 241000218691 Cupressaceae Species 0.000 claims abstract description 26
- 241000121220 Tricholoma matsutake Species 0.000 claims abstract description 26
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 23
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 23
- 241000233866 Fungi Species 0.000 claims abstract description 10
- 230000001603 reducing effect Effects 0.000 claims description 44
- 238000001035 drying Methods 0.000 claims description 36
- 241001106462 Ulmus Species 0.000 claims description 25
- 240000008397 Ganoderma lucidum Species 0.000 claims description 22
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 22
- 240000000599 Lentinula edodes Species 0.000 claims description 22
- 238000000926 separation method Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000000428 dust Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000222684 Grifola Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 244000003416 Asparagus officinalis Species 0.000 claims description 3
- 235000005340 Asparagus officinalis Nutrition 0.000 claims description 3
- 241000190633 Cordyceps Species 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 55
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 230000036541 health Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 7
- 240000001307 Myosotis scorpioides Species 0.000 abstract description 2
- 241000222336 Ganoderma Species 0.000 abstract 1
- 241000305492 Gastrodia Species 0.000 abstract 1
- 244000168667 Pholiota nameko Species 0.000 abstract 1
- 235000014528 Pholiota nameko Nutrition 0.000 abstract 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 abstract 1
- 230000006870 function Effects 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 15
- 239000005017 polysaccharide Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 150000004676 glycans Chemical class 0.000 description 14
- 239000003814 drug Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000034189 Sclerosis Diseases 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000001077 hypotensive effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 208000021822 hypotensive Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 229920001491 Lentinan Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000007443 Neurasthenia Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 241000222355 Trametes versicolor Species 0.000 description 3
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 239000002956 ash Substances 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- -1 carrotene Chemical compound 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940115286 lentinan Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 231100000244 chromosomal damage Toxicity 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000005195 poor health Effects 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- LIEMBEWXEZJEEZ-INEUFUBQSA-N (2r,3r)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-INEUFUBQSA-N 0.000 description 1
- UOYQOJGTLUOLDS-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;selenium Chemical compound [Se].OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O UOYQOJGTLUOLDS-GEMLJDPKSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- RAFAVNTVTXJMAQ-UHFFFAOYSA-N (3-hydroxyfuran-2-yl)-phenylmethanone Chemical compound OC1=C(OC=C1)C(C1=CC=CC=C1)=O RAFAVNTVTXJMAQ-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- LIEMBEWXEZJEEZ-UHFFFAOYSA-N D-threo-Leutysin Natural products NC1=NC=NC2=C1N=CN2CC(O)C(O)C(O)=O LIEMBEWXEZJEEZ-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001009581 Molluscum contagiosum virus subtype 1 Glutathione peroxidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- AJIJXGJPCVLICH-UHFFFAOYSA-N [Cl].NC(N)=O Chemical compound [Cl].NC(N)=O AJIJXGJPCVLICH-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical group Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 108010022164 acetyl-LDL Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 229940089536 indocin Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920001184 polypeptide Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗糖尿病,具有降糖作用的组合物,还涉及该组合物的制备方法,按重量百分比由鸡腿菇菌丝体25~40%、榆黄蘑菌丝体8~15%、灰树花菌丝体8~15%、冬虫夏草菌丝体4~10%、松茸菌丝体3~10%、柏树菌丝体3~10%、灵芝菌丝体3~10%、香菇菌丝体1~5%、黑木耳菌丝体1~5%、金针菇菌丝体1~5%、滑子菇菌丝体3~10%、云芝蘑菌丝体1~5%、天麻1~4%组成,本发明产品具有提高人体免疫力,安全健康,具有降糖作用,可用于治疗糖尿病。
Description
技术领域
本发明涉及一种治疗糖尿病,具有降糖作用的组合物,还涉及该组合物的制备方法。
背景技术
糖尿病是世界性的难治之症,目前市场上治疗糖尿病的药品以西药居多,对人体伤害比较大,最常用的补充胰岛素,虽然能控制糖尿病对人体的伤害,但需要终身用药,而且每天需要注射,不方便,同时还给人体千万痛苦,市场上还有一些中药治疗糖尿病的药品,但普遍疗效不佳,治疗效果不好。目前,缺乏一种具有降糖作用,可以治疗糖尿病,而且没有任何化学添加剂,绿色天然的保健品。
发明内容
本发明的目的是克服现有技术的不足,提供一种无毒副作用,具有降糖作用的组合物。本发明的另一目的是提供一种该组合物的制备方法。
本发明的一种具有降糖作用的组合物,按重量百分比由鸡腿菇菌丝体25~40%、榆黄蘑菌丝体8~15%、灰树花菌丝体8~15%、冬虫夏草菌丝体4~10%、松茸菌丝体3~10%、柏树菌丝体3~10%、灵芝菌丝体3~10%、香菇菌丝体1~5%、黑木耳菌丝体1~5%、金针菇菌丝体1~5%、滑子菇菌丝体3~10%、云芝蘑菌丝体1~5%、天麻1~4%组成。
按重量百分比,本发明的优选方案,由鸡腿菇菌丝体28~35%、榆黄蘑菌丝体10~14%、灰树花菌丝体10~14%、冬虫夏草菌丝体6~8%、松茸菌丝体5~8%、柏树菌丝体5~8%、灵芝菌丝体5~8%、香菇菌丝体2~4%、黑木耳菌丝体2~4%、金针菇菌丝体2~4%、滑子菇菌丝体5~8%、云芝蘑菌丝体2~4%、天麻1~3%组成。
按重量百分比,本发明的最优选方案,由由鸡腿菇菌丝体31%、榆黄蘑菌丝体12%、灰树花菌丝体12%、冬虫夏草菌丝体7%、松茸菌丝体6%、柏树菌丝体6%、灵芝菌丝体6%、香菇菌丝体3%、黑木耳菌丝体3%、金针菇菌丝体3%、滑子菇菌丝体6%、云芝蘑菌丝体3%、天麻2%组成。
以上所述的一种具有降糖作用的组合物,可制成任何一种药剂学上所述的剂型。
以上所述的一种具有降糖作用的组合物,优选的剂型是散剂、胶囊或片剂。
一种具有降糖作用的组合物的制备方法如下:
1、鸡腿菇菌丝体的制备方法:野生鸡腿菇经过组织分离、培养、发酵、烘干,得到鸡腿菇菌丝体;
2、榆黄蘑菌丝体的制备方法:野生榆黄蘑经过组织分离、培养、发酵、烘干,得到榆黄蘑菌丝体;
3、灰树花菌丝体的制备方法:野生灰树花经过组织分离、培养、发酵、烘干,得到灰树花菌丝体;
4、冬虫夏草菌丝体的制备方法:野生冬虫夏草经过组织分离、培养、发酵、烘干,得到冬虫夏草菌丝体;
5、松茸菌丝体的制备方法:野生松茸经过组织分离、培养、发酵、烘干,得到松茸菌丝体;
6、柏树菌丝体的制备方法:野生柏树菌经过组织分离、培养、发酵、烘干,得到柏树菌丝体;
7、灵芝菌丝体的制备方法:灵芝菌种经过培养、发酵、烘干,得到灵芝菌丝体;
8、香菇菌丝体的制备方法:香菇菌种经过培养、发酵、烘干,得到香菇菌丝体;
9、黑木耳菌丝体的制备方法:黑木耳菌种经过培养、发酵、烘干,得到黑木耳菌丝体;
10、金针菇菌丝体的制备方法:金针菇菌种经过培养、发酵、烘干,得到金针菇菌丝体;
11、滑子菇菌丝体的制备方法:滑子菇菌种经过培养、发酵、烘干,得到滑子菇菌丝体;
12、云芝蘑菌丝体的制备方法:野生云芝蘑经过组织分离、培养、发酵、烘干,得到云芝蘑菌丝体;
13、将上述制得的鸡腿菇菌丝体、榆黄蘑菌丝体、灰树花菌丝体、冬虫夏草菌丝体、松茸菌丝体、柏树菌丝体、灵芝菌丝体、香菇菌丝体、黑木耳菌丝体、金针菇菌丝体、滑子菇菌丝体、云芝蘑菌丝体分别进行粉碎、磨粉,将干燥后的天麻经过粉碎、磨粉,将上述菌丝体、天麻粉与按比例混合均匀,过80目的筛子,制成80目的细粉,就制得一种具有降糖作用的组合物的散剂;
把经灭菌处理好的散剂装入胶囊,就制得一种具有降糖作用的组合物的胶囊;
把经灭菌处理好的散剂进行压片处理,就制得一种具有降糖作用的组合物的片剂。
本发明一种具有降糖作用的组合物选择鸡腿菇菌丝体、榆黄蘑菌丝体、灰树花菌丝体、冬虫夏草菌丝体、松茸菌丝体、柏树菌丝体、灵芝菌丝体、香菇菌丝体、黑木耳菌丝体、金针菇菌丝体、滑子菇菌丝体、云芝蘑菌丝体、天麻进行组合,使得各种菌丝体功效产生协同作用,从而达到降低血糖,治疗糖尿病的目的。各种菌丝体主要成分及功效:
鸡腿菇菌丝体含有蛋白质、多糖、脂肪、粗纤维、灰粉、钙、铁等微量元素、维生素B1、B2、,8种人体必须的氨基酸等。主要功效:
(1)降血压、降血糖、降血脂、降低血清胆固醇的含量,预防动脉硬化、心脏病及肥胖病的发生。
(2)降低血糖浓度,长期大量服用对糖尿病患者有明显改善。
(3)清神益智、健脾胃、助消化、通便、幽门螺杆菌系列胃病能修复受损的粘膜。
(4)抗肿瘤、抗癌、防癌有辅助治疗。
(5)对大肠杆菌、金黄色葡萄杆菌、枯草杆菌有一定的抑制作用。
(6)对各种慢性病及免疫力低下有很好的调节作用,是调节内分泌失调的一个不可替代的保健品。
(7)对患有痔疮的病人经过服用一段时间后,会得到很好的改善。
(8)加速肝脏的解毒能力,对肠道骨有毒废物能够清除体外。
榆黄蘑菌丝体营养丰富,含蛋白质、维生素和矿物质等多种营养成分,其中氨基酸含量尤为丰富,且必需氨基酸含量高,属高营养、低热量食品,长期食用,有降低血压、降低胆固醇含量的功能,是老年人心血管疾病患者和肥胖症患者的理想保健食品。可入药,治虚弱萎症(肌萎)和痢疾等症。具有滋补强壮功效。
灰树花菌丝体具有极高的医疗保健功能。据文献报导,它有抑制高血压和肥胖症的功效;由于富含铁、铜和维他命C,它能预防贫血、坏血病、白癜风,防止动脉硬化和脑血栓的发生;它的硒和铬含量较高,有保护肝脏、胰脏,预防肝硬化和糖尿病的作用;硒含量高使其还具有防治克山病、大骨节病和某些心脏病的功能;它兼含钙和维生素D,两者配合,能有效地防治佝偻病;较高的锌含量有利大脑发育、保持视觉敏锐,促进伤口愈合;高含量的维生素E和硒配合,使之能抗衰老、增强记忆力和灵敏度。
灰树花还是引人注目的抗癌药源,一方面,较高的硒含量有抗御癌症的作用,尤其是所含灰树花多糖(Grifolan),以β-葡聚糖(glucan)为主,其中抗癌活性最强,带6条支链的β-(1,3)-葡聚糖占相当大的比重,据说比已经面市的香菇多糖(Lentinan,日本 的PSK,)、云芝多糖 (上海的PSP)等有更强的抗癌能力;同时它又是极好的免疫调节剂。作为中药,灰树花和猪苓等效,可治小便不利、水肿、脚气、肝硬化腹水及糖尿病等,是非常宝贵的药用真菌。
冬虫夏草菌丝体具有阴阳双补,起萎固精,益阴补肺之功效。虫草主要成份:虫草酸、虫草素、氨基酸、甾醇、甘露醇、生物碱、维生素 B1 、 B2 、多糖及矿物质等。主要功效:
(1)提高肾功能,对肾病可以迅速清除蛋白尿,水肿,血尿、尿素氯,血肌肝,升高血清蛋白,改善贫血,排肾毒,延缓肾功能衰竭的发生,补肾,壮阳,对男女性欲功能减退,阳萎,早泄,阴囊潮湿,腰酸腿软,头昏,耳鸣,肌肉萎缩,皮肌炎有奇特功效。
(2)对慢性气管炎有,肺源性心脏病,反复感冒,咳嗽,气喘,身体虚弱,全身瘙痒,恶心呕吐,失眠健忘,盗汗,结核杆菌,肺炎链球菌有很好的疗效。
(3)延缓细胞衰老,美容,瘦身,丰胸,预防睾丸衰老,阴阳双补。
(4)软化血管,降血脂,降血糖,改善心肌缺血,搞心律失常,镇静,抗惊厥,防止动脉硬化。
(5)对各种癌症及各种恶性肿瘤能得到改善和抑制,提高记忆力,调节内分泌系统和神经系统。
松茸菌丝体含有蛋白质、脂肪和多种氨基酸、维生素B1、B2、C和PP纤维素,不饱和脂肪酸;葡萄糖酸,核酸衍生物,肽类物质,有机锗Gel24-239PM,多糖LPB等稀有营养元素,具有提高SOD活性。主要功效:
(1)提高免疫力,增加抗病毒能力。气管炎,支气管肺炎,理气化痰,止咳平喘,肺炎双球菌,链球菌,对流感病毒有抑制作用。
(2)加速自由基的清除,延缓组织器官衰退,改善心血管功能,促进新陈代谢,提高人体免疫力,抗病毒,抗细胞突变的能力。
(3)对心脑供血不足,失眠,健忘,偏头痛,心烦,贫血,高血压,高血脂,糖尿病,动脉硬化有很好的疗效。
(4)疲乏无力,肢体困倦,胸膈满闷,恶心呕吐,脾胃功能失调,食欲不振,益胃补气,健脑益智。
(5)抗癌,抑制肿瘤,抑制癌细胞生长和扩散。
(6)补骨生髓,对骨关节疼痛有很好的疗效。
(7)对肾功能低下引起的腰酸腿软,阴囊潮湿,睾丸衰老,前列腺炎,尿频,尿痛,尿路感染,遗尿,增加肾血流量,强精补肾,恢复精力,增加雄性激素,解决性功能障碍。
柏树菌丝体富含真菌多糖、腺甘、嘌呤、嘧啶、高分子碳水化合物、纤维素等,对人体有保健治疗价值的有效成分。主要功效:
(1)增强机体免疫力,降血脂、降血压、抗癌。
(2)增强机体的稳定性、抑制肿瘤生长、抗衰老、抗过敏。
(3)抑制乙肝病毒复制,对急性肝炎、病毒性肝炎,药物对肝脏的损坏,酒精肝,肝脏疾病和肝癌都能起到保护和解毒的作用。
(4)可活化细胞、活化组织、改善微循环,双向调节人体适应机制。从而使机体恢复生理平衡。
(5)对肺结核有止痛、消炎、化积、化痰等功效。
(6)保肝、护肝、降肝火、解酒。
(7)促进儿童生长发育增长智力。
(8)抗肿瘤、防癌症。
(9)具有强肝清血功能,直接降低血液中所含的胆固醇,并疏通血管壁上的堆积物,同时也纯化了血液的品质。
灵芝菌丝体含有多糖、蛋白质、多种氨基酸、多肽类、麦角淄醇、甘露醇、生物碱、香豆精、淄体皂苷、腺嘌呤、多种酶、多种微量元素、维生素B2、维生素C等。主要功效:
(1)增强免疫功能、扶正固本、抗各种过敏体质、红斑狼疮、皮肤病、补内脏元气。
(2)白细胞减少症、白血病、长期感冒、咳喘、肺结核、淋巴结核。
(3)冠心病、心绞痛、心悸气短、心律失常、失眠多梦、降胆固醇、甘油三脂、预防动脉粥样硬化斑块的形成,改善微循环。
(4)对脾胃功能减弱、胃癌、肝癌、肿瘤都起到很好的作用。
(5)安神、镇静、抗惊厥、增智慧,对神经衰弱、头痛、头晕效果显著,对气血两虚、月经不调、痛经、闭经、更年期综合症提前更为适宜。
(6)糖尿病、进行性肌营养不良、萎缩性肌强直高源反应。抗衰老、排毒养颜。
(7)对癌症、肿瘤病人有辅助治疗,长期服用可养发护发。
香菇菌丝体含有一种分子量为100万的抗肿瘤成分——香菇多糖,含有降低血脂的成分——香菇太生,香菇腺嘌呤的衍生物,还含有抗病毒成分——干扰素的诱发剂:双链糖核酸,蛋白质18.64%、脂肪4.8%、碳水化合物71%、异亮氨酸、笨丙氨酸、蛋氨酸、苏氨酸、缬氨酸等7种人体必须的氨基酸,还含有大量的可转变维生素D的麦角淄醇和菌淄醇,B1、B2、PP及矿物盐和粗纤维,钙、磷、铁、尼克酸、可溶性无氨物质等。主要功效:
(1)降血脂、降血压、抗血栓、降血糖、安心安神、心悸、失眠、养精神、安魂魄、小儿惊厥、心腹胀满、补脑养骨髓。
(2)水湿停滞、小便不利、水肿、健脾补中益气不饥。对性病、梅毒、艾滋病、疱疹病毒、幽门螺旋杆菌、治风破血、膀胱湿热、大肠杆菌。
(3)抗病毒、防感冒、止咳、化痰、平喘、肺炎链球菌、孢子球菌有抑制作用,控制结核病的发生。
(4)健脾助消化:食欲不振、身体虚弱、大便不正常、便秘。开胃止呕、口苦舌干;逐水暖脾、生律益气、平火止泻,对肝脾肿大也有一定的好处。
(5)对婴幼儿因缺乏维生素D引起的血磷、血钙代谢障碍导致的佝偻病有很好的调节作用。
(6)对皮肤病、白血病、内分泌失调、快速增加免疫功能,使钙得到很好作用。
(7)有补肝肾、健脾胃、益气血、益智安神、养容颜之功效。
(8)对癌细胞有强烈的抑制作用:结肠癌、肺癌、乳腺癌。晚期癌症长期服用本品在化疗时间改善病人免疫功能,提高疗效、延长生存期。
黑木耳菌丝体含有多糖、麦角淄醇、维生素B2、黑刺菌素、氨基酸、蛋白质、脂质、胡萝卜素、钾、钠、钙、镁、铜、锌、锰、磷等其他微量元素。
功效:
(1)养血驻颜,令人肌肤红润、容光焕发、瘦身美容。
(2)防止缺铁性贫血、降低血管内凝血、防止动脉硬化和冠心病、脑血栓。
(3)清除血管及胃肠垃圾、活血补血、健脾胃、助排泄、减轻胃肠负担,加速胃肠内毒素和废弃物的排泄。
(4)对胆、肾结石等内源性异物有明显化解功能。
(5)降胆固醇、血脂、防止动脉硬化。
(6)对无意中吃下的头发、谷物、谷壳、木渣、沙子、金属屑等异物有溶解与氧化作用。
(7)抗辐射及抗炎、抗溃疡、抗基因突变。
(8)强心、清肺润肺、调节内分泌、失调等功能。
金针菇菌丝体含维生素B、维生素C、蛋白质、碳水化合物、矿物质、粗纤维、胡罗卜素、多种维生素、氨基酸、多糖、牛磺酸、香菇嘌呤、麦冬淄醇、细胞溶解素、冬菇细胞素等有益成分。
功效:
(1)增加智慧、提高记忆力、抗衰老,预防中老年痴呆。
(2)调节肠胃功能、防止便秘、消化道溃疡、胃肠炎、抗疲劳。
(3)清除重金属、盐类对身体的伤害,有效地增加机体的生物活性,促进体内新陈代谢,有利于食物中各种营养的吸收和利用。
(4)增强机体对癌细胞的抗御能力,降血压、降血糖、降血脂、降胆固醇,对肥胖者更为适宜。
(5)调节人体酸碱度,对早期癌症有很好的抑制作用,抗癌、防癌。
(6)抗各种细菌、病菌,对分支孢菌、枯草杆菌有抑制作用。
(7)促进儿童智力发育和健脑,对儿童、青少年生长发育缓慢、发育不良、多动症、痴呆、缺钙、缺锌现象,能增强骨骼,对钙和锌有很好的吸收。
滑子菇菌丝体富含核酸,对保持人体的精力和脑力大有益处,并且还有抑制肿瘤的作用。含有粗蛋白、脂肪、碳水化合物、粗纤维、灰分、钙、磷、铁、维生素B、维生素C、烟酸和人体所必须的其它各种氨基酸。据有关专家试验,其提取物对小白鼠s~180和艾氏腹水癌抑制率均为70%。
云芝蘑菌丝体含有一种抗癌物质。该菌药用,去湿、化痰、疗肺疾。治疗慢性支气管炎、迁延性慢性肝炎等有疗效。云芝可作为肝癌免疫治疗的药物。菌丝体提取的多糖和从发酵液中提取的多糖均具有强烈的抑癌性。对小白鼠肉瘤180和艾氏癌的抑制率分别为80%和100%。云芝蘑菌丝体还是一种有多种代谢产物的真菌,有蛋白酶、过氧化酶、淀粉酶、虫漆酶以及革酶等,有其广泛的经济用途。主要功效:
1、提高机体免疫功能:云芝菌体多糖对小鼠腹腔巨噬细胞可加强其吞噬作用,对环磷酰胺引起的脾脏萎缩具有对抗作用。云芝多糖肽(PSP)能明显增加被照射小鼠血清溶菌酶含量和脾指数,认为对巨噬细胞的非特异性免疫功能具有促进作用。干扰素诱生和促诱生的试验结果表明,云芝多糖肽的抗肿瘤和免疫调节作用可能与它具有干扰素诱生和促诱生能力有关。大鼠连续口服云芝多糖肽20g/kg/天可促进淋巴细胞转化,血清IgG滴度明显升高,还可取消大鼠隔日服环磷酰胺400mg/kg对自然杀伤细胞功能的抑制。用化学发光法观察到,云芝多糖经腹腔注射后,能增强小鼠腹腔巨噬细胞呼吸爆发功能对叔丁基氢过氧化物损伤的抵抗力。云芝多糖处理的巨噬细胞谷胱甘肽过氧化物酶(GSHPx)基础活力显著提高,在叔丁基氢过氧化物作用下,云芝多糖处理的巨噬细胞仍有较高的谷胱甘肽过氧化物酶活力。说明云芝多糖作为免疫刺激剂具有能提高抗氧化酶活力,保护巨噬细胞抵抗活性氧损伤的作用。服用云芝多糖的恶性肿瘤患者,其T3、T4淋巴细胞亚群及白细胞计数,均较眼药前显著增加,认为是一种较好的生物反应调节剂。云芝多糖对受氧化低密度脂蛋白(O-LDL)损害小鼠巨噬细胞造成的脂肪堆积,有保护作用,并能抑制巨噬细胞泡沫样变性,提高巨噬细胞反应能力。对环磷酰胺造成的小鼠白细胞减少有明显的回升作用,能激活网状内皮系统的功能。可显著提高脾细胞产生的IL-2、淋巴毒素和γ-干扰素的水平,显著增强腹腔巨噬细胞分泌肿瘤坏死因子和IL-1的能力。
2、抗肿瘤作用:云芝多糖(PSK)对肉瘤S180、白血病L1210和腺癌755均有抑制作用。肿瘤移植前10天给小鼠服用云芝提取物,对小鼠移植后12天的腹水型肉瘤S180有明显的抑制作用,移植后22天抑瘤作用减弱。不同地区的野生云芝提取物进行比较,无论陕西云芝或长白山云芝,对S180都有明显的抑瘤作用。云芝菌株在真菌体内积累多糖,还向培养液分泌胞外多糖,前者是葡聚糖,能抑制小鼠S180,并对巨噬细胞有激活作用。后者为多种单糖组成的杂多糖,有一定程度的免疫活化作用,但无明显抑瘤作用。粗制品如云芝菌丝热水提取物,对S180抑制率为77.5%,精制品活性加大,对S180抑制率达99.3%。由于PSK能明显抑制动物多种肿瘤,抗瘤谱较广,具有一定的临床疗效,故已引起广泛的注意,并已有许多资料证明其抗瘤作用是确定的。PSK由于提取方法不同,抑瘤率有所差别,实验表明:氧化还原及部分水解法提取的多糖,抑瘤作用较强。经气化、还原提取的多糖能显著延长生存率。
PSk作为化学预防剂,可作用于肿瘤细胞的生长过程,加强T细胞和自然杀伤(NK)细胞的作用,有抗畸变,预防染色体损伤和免疫调节作用。
3、抗动脉粥样硬化作用:实验证明云芝多糖(PSK)能有效地抑制动脉粥样硬化斑块的形成和发展。PSK组主动脉粥样斑块表面积明显小于对照组,心壁内冠状动脉大、中分支的狭窄程度也轻于对照组。PSK对实验性动脉粥样硬化家兔脂质过氧化损伤有保护作用,能有效地抑制脂质过氧化损伤,增强巨噬细胞硒谷胱苷肽过氧化物酶的基因表达。提高巨噬细胞免疫反应能力和抑制其泡沫样变性、对抑制动脉硬化有有益的作用,可减轻家兔动脉粥样硬化形成,对已形成粥样硬化的家兔,也有治疗作用。实验证明PSK能提高腹腔巨噬细胞对乙酰低密度脂蛋白(ac LDL)的结合,内移和降解,整体发挥降脂、抗动脉硬化作用。
4、对中枢神经系统的作用:云芝多糖(PSK)能改善小鼠和大鼠学习记忆功能,对东莨菪碱所致大鼠学习记忆障碍,有明显的改善作用。PSK能增强戊巴比妥的催眠作用,云芝多糖肽(PSP)也有一定的镇静作用,可抑制小鼠的痛反应,但起效慢,持续时间长。
5、其他作用:
5.1.降血糖作用:小鼠血糖高达362.4mg/100ml,用云芝多糖(PSK)后可降至126.6mg/100ml,对正常血糖无影响。对正常小鼠注射四氧嘧啶后血糖升高355.6mg/100ml,如预先给予PSK,则血糖仅上升至209mg/100ml,表明具有防治血糖升高作用。
5.2.PSP对大鼠应激性、幽门结扎型、醋酸型和吲哚美辛(消炎痛)型等实验性胃溃疡,有明显的抑制作用。
5.3.PSK含多种氨基酸、糖肽及多种微量元素钙、锗、镁、铁、锌等。云芝胞内多糖具有一定的抗肝炎作用,可改善体虚乏力,食欲不振等症状。PSK对乙型肝炎病毒复制有一定的抑制作用。
5.4.PSk可明显增加果蝇的吃食次数、交配次数和第一子代的仔蝇数。并延长雌蝇的平均寿命、最高寿命和半数死亡时间。但对雄蝇作用较差,并不延长平均寿命和半数死亡时间。
5.5.小鼠骨髓微核试验表明:PSK和中国提取的PV-1对致突变剂环磷酰胺引起的染色体损伤有对抗作用。对香烟烟雾染毒致突变也有对抗作用。PSK对内源性细胞毒因子的产生有促进作用。
5.6.PSK具有防止氧化损伤和抗伤害作用。对巴豆油、烟雾和内毒素等物质的致炎有对抗作用,对氯化钡致心律失常、肾上腺素诱发急性肺水肿小鼠能显著延长其存活时间和存活率。
6、毒性及不良反应:云芝多糖肽(PSP)小鼠腹腔半数致死量为300.36mg/kg,口服最大耐受量为20g/kg,尚未见小鼠死亡,说明其最小致死量MLD>20g/kg。大鼠口服PSK1.5g/kg(为临床剂量的130倍),连续60天,20只大鼠无一死亡,表明口服用药无长期毒性反应。实验表明PSK为一毒性很低的物质,也无致突变作用。
天麻含有大量天麻素,天麻苷元、香草醛、嘌呤类、海粗蛋白、脂肪、碳水化合物、纤维素、灰分等营养成分。主要功效:
(1)镇痛作用:对三叉神经痛、血管神经性头痛、脑血管性头痛、中毒性多发性神经炎等,有明显的镇痛效果。
(2)镇静作用:治疗神经衰弱和神经衰弱综合症病人,有效率分别为89.44%和86.87%,且能抑制咖啡因所致的中枢兴奋作用,还有加强戊巴妥钠的睡眠时间效应。
(3)抗惊厥作用:对面神经抽搐、肢体麻木、半身不遂、癫痫等有一定的疗效,还有缓解平滑肌痉挛,缓解心绞痛、胆绞痛的作用。
(4)降血压作用:治疗高血压,久服可平肝益气、利腰膝、强筋骨,还可增加外周及冠状动脉血流量,对心脏有保护作用。
(5)明目、增智作用:有明目和增强记忆力的作用,对学生楞保护大脑和视力,对人的大脑神经系统具有明显的保护和调节作用,能增强视神经的分辨能力,目前已用作高空飞行人员的脑保健药物,还可治疗老年性痴呆症。
纵观该具有降糖作用的组合物,是一个多种菌丝体组合在一起的,以鸡腿菇菌丝体为主,其他菌丝体为辅,组成的复方,由于组方严谨、相得益彰、功效显著。从心肝、脾肾四脏的生理特点入手,以治疗降血压、降血脂为主,调和阴阳、扶正祛邪,具有降低血糖之功效。
具体实施方式
下面结合具体实施例对本发明进一步进行描述:
实施例1:
本发明的一种具有降糖作用的组合物,按重量百分比由鸡腿菇菌丝体25%、榆黄蘑菌丝体15%、灰树花菌丝体15%、冬虫夏草菌丝体10%、松茸菌丝体10%、柏树菌丝体3%、灵芝菌丝体3%、香菇菌丝体5%、黑木耳菌丝体1%、金针菇菌丝体1%、滑子菇菌丝体3%、云芝蘑菌丝体5%、天麻4%组成。
实施例2:
本发明的一种具有降糖作用的组合物,按重量百分比由鸡腿菇菌丝体40%、榆黄蘑菌丝体8%、灰树花菌丝体8%、冬虫夏草菌丝体4%、松茸菌丝体3%、柏树菌丝体10%、灵芝菌丝体10%、香菇菌丝体1%、黑木耳菌丝体5%、金针菇菌丝体5%、滑子菇菌丝体4%、云芝蘑菌丝体1%、天麻1%组成。
实施例3:
本发明的一种具有降糖作用的组合物,按重量百分比由鸡腿菇菌丝体28%、榆黄蘑菌丝体14%、灰树花菌丝体14%、冬虫夏草菌丝体5%、松茸菌丝体5%、柏树菌丝体8%、灵芝菌丝体8%、香菇菌丝体4%、黑木耳菌丝体2%、金针菇菌丝体2%、滑子菇菌丝体5%、云芝蘑菌丝体2%、天麻3%组成。
实施例4:
本发明的一种具有降糖作用的组合物,按重量百分比由鸡腿菇菌丝体35%、榆黄蘑菌丝体10%、灰树花菌丝体10%、冬虫夏草菌丝体8%、松茸菌丝体8%、柏树菌丝体5%、灵芝菌丝体5%、香菇菌丝体2%、黑木耳菌丝体2%、金针菇菌丝体2%、滑子菇菌丝体8%、云芝蘑菌丝体4%、天麻1%组成。
实施例5:
本发明的一种具有降糖作用的组合物,按重量百分比由鸡腿菇菌丝体31%、榆黄蘑菌丝体12%、灰树花菌丝体12%、冬虫夏草菌丝体7%、松茸菌丝体6%、柏树菌丝体6%、灵芝菌丝体6%、香菇菌丝体3%、黑木耳菌丝体3%、金针菇菌丝体3%、滑子菇菌丝体6%、云芝蘑菌丝体3%、天麻2%组成。
实施例6:
制备具有降糖作用的组合物:
制备鸡腿菇菌丝体:野生鸡腿菇经过组织分离、培养、发酵、烘干,得到鸡腿菇菌丝体;
制备榆黄蘑菌丝体:野生榆黄蘑经过组织分离、培养、发酵、烘干,得到榆黄蘑菌丝体;
制备灰树花菌丝体:野生灰树花经过组织分离、培养、发酵、烘干,得到灰树花菌丝体;
制备冬虫夏草菌丝体:野生冬虫夏草经过组织分离、培养、发酵、烘干,得到冬虫夏草菌丝体;
制备松茸菌丝体:野生松茸经过组织分离、培养、发酵、烘干,得到松茸菌丝体;
制备柏树菌丝体:野生柏树菌经过组织分离、培养、发酵、烘干,得到柏树菌丝体;
制备灵芝菌丝体:灵芝菌种经过培养、发酵、烘干,得到灵芝菌丝体;
制备香菇菌丝体:香菇菌种经过培养、发酵、烘干,得到香菇菌丝体;
制备黑木耳菌丝体:黑木耳菌种经过培养、发酵、烘干,得到黑木耳菌丝体;
制备金针菇菌丝体:金针菇菌种经过培养、发酵、烘干,得到金针菇菌丝体;
制备滑子菇菌丝体:滑子菇菌种经过培养、发酵、烘干,得到滑子菇菌丝体;
制备云芝蘑菌丝体:野生云芝蘑经过组织分离、培养、发酵、烘干,得到云芝蘑菌丝体;
将上述制得的鸡腿菇菌丝体、榆黄蘑菌丝体、灰树花菌丝体、冬虫夏草菌丝体、松茸菌丝体、柏树菌丝体、灵芝菌丝体、香菇菌丝体、黑木耳菌丝体、金针菇菌丝体、滑子菇菌丝体、云芝蘑菌丝体分别进行粉碎、磨粉,将干燥后的天麻经过粉碎、磨粉,将上述菌丝体、天麻粉与按比例混合均匀,过80目的筛子,制成80目的细粉,就制得一种具有降糖作用的组合物的散剂;
把经灭菌处理好的散剂装入胶囊,就制得一种具有降糖作用的组合物的胶囊;
把经灭菌处理好的散剂进行压片处理,就制得一种具有降糖作用的组合物的片剂。
也可以把经灭菌处理好的散剂,装入袋子里,浸泡在酒中,制成具有降糖作用的保健酒。
本发明一种具有降糖作用的组合物的降低血糖治疗效果:
在患者同意的情况下,使用该具有降糖作用的组合物,对86例糖尿病患者进行了治疗。在病人自愿的前提下,服用本发明的具有降糖作用的组合物,每日二次,每次2~3克,早饭前、晚上睡觉前服用,温水送服,连服15天,为1疗程,连续服用6个疗程。
治疗效果: 32例患者血糖基本正常,41例患者血糖得到一定程度的降低,上述73例患者身体健康状况得到明显改善,13例患者没有明显效果。总结:41例患者临床基本上治癒,治癒率47.7%,73例患者身体健康状况得到明显改善,在提高身体健康状况方面的有效率为84.9%。
Claims (6)
1.一种具有降糖作用的组合物,其特征在于:按重量百分比由鸡腿菇菌丝体25~40%、榆黄蘑菌丝体8~15%、灰树花菌丝体8~15%、冬虫夏草菌丝体4~10%、松茸菌丝体3~10%、柏树菌丝体3~10%、灵芝菌丝体3~10%、香菇菌丝体1~5%、黑木耳菌丝体1~5%、金针菇菌丝体1~5%、滑子菇菌丝体3~10%、云芝蘑菌丝体1~5%、天麻1~4%组成。
2.根据权利要求1所述的一种具有降糖作用的组合物,其特征在于:按重量百分比由鸡腿菇菌丝体28~35%、榆黄蘑菌丝体10~14%、灰树花菌丝体10~14%、冬虫夏草菌丝体6~8%、松茸菌丝体5~8%、柏树菌丝体5~8%、灵芝菌丝体5~8%、香菇菌丝体2~4%、黑木耳菌丝体2~4%、金针菇菌丝体2~4%、滑子菇菌丝体5~8%、云芝蘑菌丝体2~4%、天麻1~3%组成。
3.根据权利要求2所述的一种具有降糖作用的组合物,其特征在于:按重量百分比由鸡腿菇菌丝体31%、榆黄蘑菌丝体12%、灰树花菌丝体12%、冬虫夏草菌丝体7%、松茸菌丝体6%、柏树菌丝体6%、灵芝菌丝体6%、香菇菌丝体3%、黑木耳菌丝体3%、金针菇菌丝体3%、滑子菇菌丝体6%、云芝蘑菌丝体3%、天麻2%组成。
4.根据权利要求1~3任一所述的一种具有降糖作用的组合物,其特征在于:所述的剂型是任何一种药剂学上所述的剂型。
5.根据权利要求4所述的一种具有降糖作用的组合物,其特征在于:所述的剂型是散剂、胶囊或片剂。
6.根据权利要求1~5任一所述的一种具有降糖作用的组合物的制备方法,其特征在于包括以下步骤:
1)鸡腿菇菌丝体的制备方法:野生鸡腿菇经过组织分离、培养、发酵、烘干,得到鸡腿菇菌丝体;
2)榆黄蘑菌丝体的制备方法:野生榆黄蘑经过组织分离、培养、发酵、烘干,得到榆黄蘑菌丝体;
3)灰树花菌丝体的制备方法:野生灰树花经过组织分离、培养、发酵、烘干,得到灰树花菌丝体;
4)冬虫夏草菌丝体的制备方法:野生冬虫夏草经过组织分离、培养、发酵、烘干,得到冬虫夏草菌丝体;
5)松茸菌丝体的制备方法:野生松茸经过组织分离、培养、发酵、烘干,得到松茸菌丝体;
6)柏树菌丝体的制备方法:野生柏树菌经过组织分离、培养、发酵、烘干,得到柏树菌丝体;
7)灵芝菌丝体的制备方法:灵芝菌种经过培养、发酵、烘干,得到灵芝菌丝体;
8)香菇菌丝体的制备方法:香菇菌种经过培养、发酵、烘干,得到香菇菌丝体;
9)黑木耳菌丝体的制备方法:黑木耳菌种经过培养、发酵、烘干,得到黑木耳菌丝体;
10)金针菇菌丝体的制备方法:金针菇菌种经过培养、发酵、烘干,得到金针菇菌丝体;
11)滑子菇菌丝体的制备方法:滑子菇菌种经过培养、发酵、烘干,得到滑子菇菌丝体;
12)云芝蘑菌丝体的制备方法:野生云芝蘑经过组织分离、培养、发酵、烘干,得到云芝蘑菌丝体;
13)将上述制得的鸡腿菇菌丝体、榆黄蘑菌丝体、灰树花菌丝体、冬虫夏草菌丝体、松茸菌丝体、柏树菌丝体、灵芝菌丝体、香菇菌丝体、黑木耳菌丝体、金针菇菌丝体、滑子菇菌丝体、云芝蘑菌丝体分别进行粉碎、磨粉,将干燥后的天麻经过粉碎、磨粉,将上述菌丝体、天麻粉与按比例混合均匀,就制得一种具有降糖作用的组合物的散剂;
14)把经灭菌处理好的散剂装入胶囊,就制得一种具有降糖作用的组合物的胶囊;
15)把经灭菌处理好的散剂进行压片处理,就制得一种具有降糖作用的组合物的片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410376269.XA CN104126785A (zh) | 2014-08-03 | 2014-08-03 | 一种具有降糖作用的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410376269.XA CN104126785A (zh) | 2014-08-03 | 2014-08-03 | 一种具有降糖作用的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104126785A true CN104126785A (zh) | 2014-11-05 |
Family
ID=51799835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410376269.XA Pending CN104126785A (zh) | 2014-08-03 | 2014-08-03 | 一种具有降糖作用的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104126785A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104523982A (zh) * | 2014-11-25 | 2015-04-22 | 李志成 | 一种保肝健肾排毒降脂的药物及其制备方法 |
CN106074713A (zh) * | 2016-08-10 | 2016-11-09 | 翔天农业开发集团股份有限公司 | 一种降压保健口服液及其制备方法 |
CN106235314A (zh) * | 2016-08-10 | 2016-12-21 | 翔天农业开发集团股份有限公司 | 一种高效保健口服液及其制备方法 |
CN106266231A (zh) * | 2016-08-10 | 2017-01-04 | 翔天农业开发集团股份有限公司 | 一种可提高免疫力的保健品及其制备方法 |
CN107095300A (zh) * | 2017-03-08 | 2017-08-29 | 辽宁山水源植物科技有限公司 | 一种辅助治疗糖尿病的生物营养配方组合物 |
CN107156801A (zh) * | 2016-03-08 | 2017-09-15 | 及长城 | 一种具有生发的活性菌丝群组合物及其制备方法 |
CN107519400A (zh) * | 2016-06-20 | 2017-12-29 | 及长城 | 一种具有降三高作用的生物组合物及其制备方法 |
CN118077881A (zh) * | 2024-04-18 | 2024-05-28 | 潘振远 | 一种具有清除体内垃圾毒素作用的组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1149981A (zh) * | 1995-11-16 | 1997-05-21 | 姜国华 | 保健饲料 |
CN1342425A (zh) * | 2000-09-11 | 2002-04-03 | 张国防 | 一种营养食品及其生产方法 |
CN101085233A (zh) * | 2007-06-13 | 2007-12-12 | 夏熙邦 | 降血压、血脂、血糖的民间中草药 |
-
2014
- 2014-08-03 CN CN201410376269.XA patent/CN104126785A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1149981A (zh) * | 1995-11-16 | 1997-05-21 | 姜国华 | 保健饲料 |
CN1342425A (zh) * | 2000-09-11 | 2002-04-03 | 张国防 | 一种营养食品及其生产方法 |
CN101085233A (zh) * | 2007-06-13 | 2007-12-12 | 夏熙邦 | 降血压、血脂、血糖的民间中草药 |
Non-Patent Citations (1)
Title |
---|
陶美华等: "几种药用真菌粗提物降糖功能研究", 《2008全国药用真菌学术研讨会论文集》, 31 December 2008 (2008-12-31), pages 213 - 218 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104523982A (zh) * | 2014-11-25 | 2015-04-22 | 李志成 | 一种保肝健肾排毒降脂的药物及其制备方法 |
CN107156801A (zh) * | 2016-03-08 | 2017-09-15 | 及长城 | 一种具有生发的活性菌丝群组合物及其制备方法 |
CN107519400A (zh) * | 2016-06-20 | 2017-12-29 | 及长城 | 一种具有降三高作用的生物组合物及其制备方法 |
CN106074713A (zh) * | 2016-08-10 | 2016-11-09 | 翔天农业开发集团股份有限公司 | 一种降压保健口服液及其制备方法 |
CN106235314A (zh) * | 2016-08-10 | 2016-12-21 | 翔天农业开发集团股份有限公司 | 一种高效保健口服液及其制备方法 |
CN106266231A (zh) * | 2016-08-10 | 2017-01-04 | 翔天农业开发集团股份有限公司 | 一种可提高免疫力的保健品及其制备方法 |
CN107095300A (zh) * | 2017-03-08 | 2017-08-29 | 辽宁山水源植物科技有限公司 | 一种辅助治疗糖尿病的生物营养配方组合物 |
CN118077881A (zh) * | 2024-04-18 | 2024-05-28 | 潘振远 | 一种具有清除体内垃圾毒素作用的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2689951C1 (ru) | Способ производства грибов | |
CN104126785A (zh) | 一种具有降糖作用的组合物及其制备方法 | |
CN103355556B (zh) | 一种玉米型断奶仔猪配合饲料及其制备方法 | |
CN104147383A (zh) | 一种抗肿瘤的组合物及其制备方法 | |
CN101023802A (zh) | 全营养绿色保健粉(丝、条)和方便(速食)粉(丝、条)系列产品及其制作方法 | |
CN106473107A (zh) | 一种即食型复合食用菌粉营养素及其制备方法 | |
CN102008516B (zh) | 一种治疗肿瘤的超微粉中药 | |
CN104147132A (zh) | 能够降低血糖调节胰岛素分泌的软胶囊及制作方法 | |
CN102144748A (zh) | 具有排毒护肝养颜功能的五色面制食品 | |
CN102488278A (zh) | 一种具有双功能保健作用的复合真菌营养液 | |
CN102755346A (zh) | 一种食用真菌复合多糖配方、制备方法及其应用 | |
CN103877122A (zh) | 中药阿胶原料的生产方法及其产品 | |
CN104106799B (zh) | 一种具有清除体内毒素作用的组合物及其制备方法 | |
CN105288226A (zh) | 一种补肾壮阳的组合物及其制备方法 | |
JP2011184349A (ja) | 頻尿改善組成物、健康食品、及び血流改善組成物 | |
CN107997125A (zh) | 食用菌菌丝体和\或食用菌菌丝体粉制作工艺及其产品 | |
CN104906140A (zh) | 一种阿胶及其制备方法与相关设备 | |
CN105361149A (zh) | 一种青稞虫草糁子营养粉及其制备方法 | |
CN102784163A (zh) | 一种食用菌类复合多糖养生保健治疗配方及其制备方法 | |
CN109620858A (zh) | 防治糖尿病的药食同源制剂 | |
CN107519400A (zh) | 一种具有降三高作用的生物组合物及其制备方法 | |
CN109043325A (zh) | 一种食用复合菌粉 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
JPH0767576A (ja) | 菌糸体健康食材 | |
CN115176953A (zh) | 一种健脾益气、补虚固本,辅助抗肿瘤的菌菇多糖配伍 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141105 |
|
WD01 | Invention patent application deemed withdrawn after publication |